Vancomycin MIC and agr dysfunction in invasive MRSA infections in southern Brazil
Open Access
- 19 October 2020
- journal article
- research article
- Published by Springer Nature in Brazilian Journal of Microbiology
- Vol. 51 (4) , 1819-1823
Abstract
In methicillin-resistant Staphylococcus aureus (MRSA) treatment, the vancomycin minimum inhibitory concentration (MIC) increase, vancomycin heteroresistance (hVISA) presence, and accessory gene regulator (agr) dysfunction are predictors of vancomycin therapy failure. This study evaluated the association between vancomycin MIC (≥ 1.0 μg/mL) and agr dysfunction in invasive MRSA isolates. Vancomycin MIC, hVISA phenotype, agr group, and function were determined in 171 MRSA isolates obtained between 2014 and 2019 from hospitals in Porto Alegre, Brazil. All MRSA were susceptible to vancomycin; 16.4% of these had MIC ≥ 1.0 μg/mL. Seventeen MRSA isolates expressed the hVISA phenotype; 35.3% of them had MIC of 1.5 μg/mL. agr groups I (40.9%) and II (47.1%) were the most found groups for MRSA and hVISA isolates, respectively. The proportion of MRSA with vancomycin MIC ≥ 1.0 μg/mL in agr group II was significantly higher than in agr groups I and III (p = 0.002). agr dysfunction was observed in 4.7% (8/171) of MRSA, especially those with vancomycin MIC ≥ 1.0 μg/mL (p < 0.001). In addition, six isolates (35.3%; 6/17) with hVISA phenotype presented agr dysfunction, which was significantly higher than that in non-hVISA phenotype (p < 0.001). In conclusion, agr dysfunction in MRSA is associated with vancomycin MIC ≥ 1.0 μg/mL and hVISA phenotype, which suggests that agr dysfunction might confer potential advantages on MRSA to survive in invasive infections.Keywords
Funding Information
- Foundation of the State of Rio Grande do Sul (FAPERGS). (FAPERGS - 02/2017 PqG)
This publication has 30 references indexed in Scilit:
- Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream InfectionAntimicrobial Agents and Chemotherapy, 2013
- The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysisClinical Infectious Diseases, 2012
- Detection of Staphylococcus aureus Isolates with Heterogeneous Intermediate-Level Resistance to Vancomycin in the United StatesJournal of Clinical Microbiology, 2011
- Relationship of agr Expression and Function with Virulence and Vancomycin Treatment Outcomes in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2011
- Characterization of heterogeneous vancomycin-intermediate resistance, MIC and accessory gene regulator (agr) dysfunction among clinical bloodstream isolates of staphyloccocus aureusBMC Infectious Diseases, 2011
- Is There a Clinical Association of Vancomycin MIC Creep, agr Group II Locus, and Treatment Failure in MRSA Bacteremia?Diagnostic Molecular Pathology, 2011
- The Interface Between Antibiotic Resistance and Virulence in Staphylococcus aureus and Its Impact Upon Clinical OutcomesClinical Infectious Diseases, 2011
- Superantigen gene profiles and presence of exfoliative toxin genes in community-acquired meticillin-resistant Staphylococcus aureus isolated from Chinese childrenJournal of Medical Microbiology, 2011
- Accessory Gene Regulator Dysfunction: An Advantage forStaphylococcus aureusin Health‐Care Settings?The Journal of Infectious Diseases, 2009
- Molecular Mechanisms of agr Quorum Sensing in Virulent StaphylococciChemBioChem, 2007